scholarly journals P487. The effect of a coordinated care programme for inflammatory bowel diseases on health care utilisation

2016 ◽  
Vol 10 (suppl 1) ◽  
pp. S347.1-S347
2017 ◽  
Vol 11 (suppl_1) ◽  
pp. S257-S257
Author(s):  
A. Zand ◽  
E. Aredas ◽  
N. Duran ◽  
C. DiNicola ◽  
P. Lacey ◽  
...  

2014 ◽  
Vol 20 (10) ◽  
pp. 1747-1753 ◽  
Author(s):  
Welmoed K. van Deen ◽  
Martijn G. H. van Oijen ◽  
Kelly D. Myers ◽  
Adriana Centeno ◽  
William Howard ◽  
...  

2017 ◽  
Vol 152 (5) ◽  
pp. S790
Author(s):  
Aria Zand ◽  
Elizabeth Aredas ◽  
Natalie E. Duran ◽  
Courtney A. DiNicola ◽  
Precious Lacey ◽  
...  

2019 ◽  
Vol 13 (6) ◽  
pp. 744-754 ◽  
Author(s):  
Nadia Pillai ◽  
Mark Dusheiko ◽  
Michel H Maillard ◽  
Gerhard Rogler ◽  
Beat Brüngger ◽  
...  

2018 ◽  
Vol 1 (1) ◽  
pp. 120-128 ◽  
Author(s):  
Shota Saito ◽  
Kyoko Nakazawa ◽  
Kenji Suzuki ◽  
Takashi Ishikawa ◽  
Kouhei Akazawa

Anti-tumor necrosis factor-α (anti-TNFα) agents are used for induction and maintenance of remission in patients with inflammatory bowel diseases (IBD). However, biologic drugs present a large economic burden on health insurance systems. We aimed to estimate the mean annual health care cost per patient with IBD and cost contribution of anti-TNFα agents. We performed an analysis of patients with Crohn’s disease (CD) and ulcerative colitis (UC) based on a large-scale administrative claims database constructed by Japan Medical Data Center (JMDC) Co. Ltd., comprising inpatient, outpatient, and pharmacy claims data. We evaluated all claims from 1 April 2013 through 31 March 2016. Descriptive statistics were used to measure median health care costs paid per member per year (PMPY) and the relative cost contribution of anti-TNFα agents. A total 1405 patients with CD and 5771 with UC were included. Median costs PMPY were approximately six times higher for CD than UC (JPY 1,957,320 and JPY 278,760, respectively). Medication cost for anti-TNFα agents was the main cost driver, accounting for 59.9% and 17.8% of the total costs for CD and UC, respectively. In Japan, costs for anti-TNFα agents have resulted in drug costs exceeding inpatient costs for IBD. Optimized use of anti-TNFα agents and introduction of biosimilars for anti-TNFα agents can be expected to substantially reduce the health care costs of IBD.


2016 ◽  
Vol 150 (4) ◽  
pp. S70-S71 ◽  
Author(s):  
Welmoed K. van Deen ◽  
Martha Skup ◽  
Adriana Centeno ◽  
Natalie E. Duran ◽  
Precious Lacey ◽  
...  

2010 ◽  
Vol 12 (3) ◽  
pp. 273-283 ◽  
Author(s):  
Anne Prenzler ◽  
Bernd Bokemeyer ◽  
J.-Matthias von der Schulenburg ◽  
Thomas Mittendorf

2019 ◽  
Vol 17 (10) ◽  
pp. 2050-2059.e1 ◽  
Author(s):  
Valérie E.H. Pittet ◽  
Michel H. Maillard ◽  
Thomas Simonson ◽  
Nicolas Fournier ◽  
Gerhard Rogler ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document